StockScan › Stocks › KZIA
KZIA
(NASDAQ)
10.18
+0.33   (+3.35%)
After Hours: 10.13 -0.0501 (-0.49%)
Volume (24h) Market Cap. Day Range 52w Range
179.43K 95.32M 9.90 - 10.30 2.50 - 15.85
Company Info
Name
Name
Novogen Limited - American Depo
Sector
Healthcare (1003)
Industry
Biotechnology (590)
Web
kaziatherapeutics.com
Phone
61 2 9472 4101
Employee
0
Twitter
 @KaziaTx
SEC filings
 Latest SEC Filings
Address
Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, NSW, Australia (2000)
Gainers ›
% (24h)
CDR
+552.90%
ORMP
+37.77%
SOL
+32.86%
APXT
+29.21%
NK
+28.25%
ARCT
+25.35%
JG
+23.42%
Losers ›
% (24h)
YJ
-22.72%
NBAC
-22.32%
FTFT
-20.33%
MARA
-16.41%
BTBT
-13.07%
RIOT
-11.72%
CAN
-9.73%
Top Screener
Penny Stocks
52 Week Low
52 Week High
NewsNews OptionsOptions FinancialsFinancials HoldersHolders TransactionsTransactions DiscussionsDiscussions
Nov-26-20 02:14AM Should You Take Comfort From Insider Transactions At Kazia Therapeutics Limited (ASX:KZA)?Simply Wall St.
Nov-19-20 08:17AM The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets UnderwayBenzinga
Nov-18-20 07:29AM The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study LiftedBenzinga
Nov-17-20 06:39AM Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In GlioblastomaPR Newswire
05:47AM Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In GlioblastomaPR Newswire
Oct-16-20 10:30AM Kazia Executes Agreement To Commence GBM Agile Pivotal StudyPR Newswire
Oct-15-20 07:30AM Kazia Executes Agreement To Commence GBM Agile Pivotal StudyPR Newswire
Sep-22-20 10:00AM Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS LymphomaPR Newswire
Sep-21-20 09:21AM Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS LymphomaPR Newswire
Sep-02-20 10:15AM Edison issues ADR outlook on Kazia Therapeutics (KZIA)ACCESSWIRE
Sep-01-20 01:23AM We're Hopeful That Kazia Therapeutics (ASX:KZA) Will Use Its Cash WiselySimply Wall St.
Aug-23-20 09:14AM US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPGPR Newswire
Aug-20-20 10:30AM US FDA Awards Fast Track Designation (FTD) to Paxalisib for GlioblastomaPR Newswire
Aug-07-20 10:30AM US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPGPR Newswire
Jun-22-20 10:30AM Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both DrugsPR Newswire
Jun-01-20 10:30AM Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival SignalPR Newswire
May-29-20 04:34AM Iain Ross Is The Independent Chairman of the Board of Kazia Therapeutics Limited (ASX:KZA) And They Just Picked Up 19% More SharesSimply Wall St.
May-25-20 12:49PM Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?Simply Wall St.
Apr-07-20 08:00AM Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma StudyPR Newswire
Feb-24-20 04:34AM Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?Simply Wall St.
Jan-13-20 07:55AM Edison issues ADR update on Kazia Therapeutics (KZIA)ACCESSWIRE
Dec-11-19 10:00AM Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in GlioblastomaPR Newswire
Dec-02-19 08:45AM Edison issues ADR outlook on Kazia Therapeutics (KZIA)ACCESSWIRE
Nov-28-19 05:12AM If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%Simply Wall St.
Nov-25-19 10:00AM Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO ConferencePR Newswire
Oct-27-19 10:16AM Kazia Raises A$4.0 Million to Progress R&D ProgramsPR Newswire
Sep-13-19 08:00AM Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancerPR Newswire
Jul-22-19 09:00AM Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer CenterPR Newswire
Jul-17-19 08:00AM Kazia calls for greater awareness of the deadliest brain cancer in the USPR Newswire
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Open in Yahoo | Open in Google | Open in Finviz
Cap:    |  Volume (24h):